Calidi Biotherapeutics, Inc. Payments of Stock Issuance Costs
Calidi Biotherapeutics, Inc. (CLDI) reported Payments of Stock Issuance Costs of $2.34 million for the 9-month period ending 2021-12-31, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2023-03-31
- Calidi Biotherapeutics, Inc. payments of stock issuance costs for the quarter ending 2021-12-31 was $0.00.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month |
|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 9 month − 10-Q 6 month · filed 2023-03-31 | $2.34M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $2.34M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |